JP2009515984A - キナーゼ阻害剤として有用なアザインダゾール - Google Patents
キナーゼ阻害剤として有用なアザインダゾール Download PDFInfo
- Publication number
- JP2009515984A JP2009515984A JP2008541312A JP2008541312A JP2009515984A JP 2009515984 A JP2009515984 A JP 2009515984A JP 2008541312 A JP2008541312 A JP 2008541312A JP 2008541312 A JP2008541312 A JP 2008541312A JP 2009515984 A JP2009515984 A JP 2009515984A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- hydrogen
- formula
- aliphatic
- aliphatic group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 C*c1nc2ccccc2[n]1 Chemical compound C*c1nc2ccccc2[n]1 0.000 description 4
- DETZLELRFGGBPZ-UHFFFAOYSA-N C=[S](c1n[nH]c2ncccc12)(N(CC1)CCC1(c(cc1)ccc1F)O)(=O)=O Chemical compound C=[S](c1n[nH]c2ncccc12)(N(CC1)CCC1(c(cc1)ccc1F)O)(=O)=O DETZLELRFGGBPZ-UHFFFAOYSA-N 0.000 description 1
- BGNLXETYTAAURD-UHFFFAOYSA-N CC(C)(C)C(CC1)CCC1N Chemical compound CC(C)(C)C(CC1)CCC1N BGNLXETYTAAURD-UHFFFAOYSA-N 0.000 description 1
- ACWKGWXBEOOZBP-UHFFFAOYSA-N CC(C)(C1)CC(C)(CNS(c2n[nH]c3ncccc23)(=O)=O)CC1O Chemical compound CC(C)(C1)CC(C)(CNS(c2n[nH]c3ncccc23)(=O)=O)CC1O ACWKGWXBEOOZBP-UHFFFAOYSA-N 0.000 description 1
- OOGQDLFTEKMAGJ-UHFFFAOYSA-N CC(C)C(C(C)C)NS(c1n[nH]c2ncccc12)(=O)=O Chemical compound CC(C)C(C(C)C)NS(c1n[nH]c2ncccc12)(=O)=O OOGQDLFTEKMAGJ-UHFFFAOYSA-N 0.000 description 1
- FEYCIHWJGGKIDG-UHFFFAOYSA-N CC(C)C(C1)NN=C1c1ccccc1 Chemical compound CC(C)C(C1)NN=C1c1ccccc1 FEYCIHWJGGKIDG-UHFFFAOYSA-N 0.000 description 1
- BGNWXRJWDQHCRB-UHFFFAOYSA-N CC(C)c1ncccn1 Chemical compound CC(C)c1ncccn1 BGNWXRJWDQHCRB-UHFFFAOYSA-N 0.000 description 1
- UKHGPTXZGMIHIN-UHFFFAOYSA-N CC(C)c1nnc[s]1 Chemical compound CC(C)c1nnc[s]1 UKHGPTXZGMIHIN-UHFFFAOYSA-N 0.000 description 1
- RVISOWROPPCWIN-UHFFFAOYSA-N CC(CC1)CCN1S(c1n[nH]c2ncccc12)(=O)=O Chemical compound CC(CC1)CCN1S(c1n[nH]c2ncccc12)(=O)=O RVISOWROPPCWIN-UHFFFAOYSA-N 0.000 description 1
- QYZHILGPXWODHI-UHFFFAOYSA-N CC(CCC1)N1S(c1n[nH]c2ncccc12)(=O)=O Chemical compound CC(CCC1)N1S(c1n[nH]c2ncccc12)(=O)=O QYZHILGPXWODHI-UHFFFAOYSA-N 0.000 description 1
- XYCAYURERXFPFG-UHFFFAOYSA-N CC(CCC1C)N1S(c1n[nH]c2ncccc12)(=O)=O Chemical compound CC(CCC1C)N1S(c1n[nH]c2ncccc12)(=O)=O XYCAYURERXFPFG-UHFFFAOYSA-N 0.000 description 1
- PTKVQEISAHZHMF-UHFFFAOYSA-N CC(CO)(CO)NS(Cc1n[nH]c2ncccc12)(=O)=O Chemical compound CC(CO)(CO)NS(Cc1n[nH]c2ncccc12)(=O)=O PTKVQEISAHZHMF-UHFFFAOYSA-N 0.000 description 1
- YIDRKEOGDSLZHH-UHFFFAOYSA-N CCC(Cc1cc(O)c(C)cc1)NS(c1n[nH]c2ncccc12)(=O)=O Chemical compound CCC(Cc1cc(O)c(C)cc1)NS(c1n[nH]c2ncccc12)(=O)=O YIDRKEOGDSLZHH-UHFFFAOYSA-N 0.000 description 1
- YAYPGXWVKQPKIE-UHFFFAOYSA-N COc1cccc(OC)c1CNS(c1n[nH]c2ncccc12)(=O)=O Chemical compound COc1cccc(OC)c1CNS(c1n[nH]c2ncccc12)(=O)=O YAYPGXWVKQPKIE-UHFFFAOYSA-N 0.000 description 1
- GHTVAOBQFFQEOL-UHFFFAOYSA-N Cc1c(CN[S](c2n[nH]c3ncccc23)(=C)(=O)=O)c(Cl)cc(Cl)c1 Chemical compound Cc1c(CN[S](c2n[nH]c3ncccc23)(=C)(=O)=O)c(Cl)cc(Cl)c1 GHTVAOBQFFQEOL-UHFFFAOYSA-N 0.000 description 1
- VZWOXDYRBDIHMA-UHFFFAOYSA-N Cc1ncc[s]1 Chemical compound Cc1ncc[s]1 VZWOXDYRBDIHMA-UHFFFAOYSA-N 0.000 description 1
- KSCNOSBFEDSBOM-UHFFFAOYSA-N Ic1nnc[nH]1 Chemical compound Ic1nnc[nH]1 KSCNOSBFEDSBOM-UHFFFAOYSA-N 0.000 description 1
- ZGGWCNZTBGCNNR-QMMMGPOBSA-N NC([C@H](CCC1)N1S(C(c1cccnc1N)=N)(=O)=O)=O Chemical compound NC([C@H](CCC1)N1S(C(c1cccnc1N)=N)(=O)=O)=O ZGGWCNZTBGCNNR-QMMMGPOBSA-N 0.000 description 1
- PBIZEUZJQKXYMI-UHFFFAOYSA-N O=S(Cc1n[nH]c2ncccc12)(N1CCCCC1)=O Chemical compound O=S(Cc1n[nH]c2ncccc12)(N1CCCCC1)=O PBIZEUZJQKXYMI-UHFFFAOYSA-N 0.000 description 1
- PDYNVUZAPLLGFC-UHFFFAOYSA-N O=S(c1n[nH]c2ncccc12)(N1CCCC1)=O Chemical compound O=S(c1n[nH]c2ncccc12)(N1CCCC1)=O PDYNVUZAPLLGFC-UHFFFAOYSA-N 0.000 description 1
- NCHJJCOSANPWCD-LBPRGKRZSA-N O=S(c1n[nH]c2ncccc12)(N1[C@H](CN2CCCC2)CCC1)=O Chemical compound O=S(c1n[nH]c2ncccc12)(N1[C@H](CN2CCCC2)CCC1)=O NCHJJCOSANPWCD-LBPRGKRZSA-N 0.000 description 1
- WQUONYBNJSESNC-UHFFFAOYSA-N O=S(c1n[nH]c2ncccc12)(NCCC1=CCCCC1)=O Chemical compound O=S(c1n[nH]c2ncccc12)(NCCC1=CCCCC1)=O WQUONYBNJSESNC-UHFFFAOYSA-N 0.000 description 1
- QZYZIJINMKSVSH-UHFFFAOYSA-N O=S(c1n[nH]c2ncccc12)(NCCSCc(c(F)ccc1)c1Cl)=O Chemical compound O=S(c1n[nH]c2ncccc12)(NCCSCc(c(F)ccc1)c1Cl)=O QZYZIJINMKSVSH-UHFFFAOYSA-N 0.000 description 1
- BKJFFUUKALQKBS-UHFFFAOYSA-N O=S(c1n[nH]c2ncccc12)(NCCSc1c(cccc2)c2nc(C(F)(F)F)c1)=O Chemical compound O=S(c1n[nH]c2ncccc12)(NCCSc1c(cccc2)c2nc(C(F)(F)F)c1)=O BKJFFUUKALQKBS-UHFFFAOYSA-N 0.000 description 1
- FSTFQBBSKFGDFF-UHFFFAOYSA-N OC(CC1)CN1S(c1n[nH]c2ncccc12)=O Chemical compound OC(CC1)CN1S(c1n[nH]c2ncccc12)=O FSTFQBBSKFGDFF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73710505P | 2005-11-15 | 2005-11-15 | |
| PCT/US2006/044361 WO2007059219A1 (en) | 2005-11-15 | 2006-11-15 | Azaindazoles useful as inhibitors of kinases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009515984A true JP2009515984A (ja) | 2009-04-16 |
| JP2009515984A5 JP2009515984A5 (https=) | 2010-01-07 |
Family
ID=37860677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008541312A Pending JP2009515984A (ja) | 2005-11-15 | 2006-11-15 | キナーゼ阻害剤として有用なアザインダゾール |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8017781B2 (https=) |
| EP (2) | EP1948657A1 (https=) |
| JP (1) | JP2009515984A (https=) |
| CN (1) | CN101365700A (https=) |
| AU (1) | AU2006315436A1 (https=) |
| CA (1) | CA2628179A1 (https=) |
| WO (1) | WO2007059219A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019532054A (ja) * | 2016-09-20 | 2019-11-07 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | Trpv4拮抗薬 |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7553639B2 (en) * | 2006-01-31 | 2009-06-30 | Elan Pharma International Limited | Alpha-synuclein kinase |
| CN101790532B (zh) * | 2007-07-31 | 2013-11-20 | 沃泰克斯药物股份有限公司 | 5-氟-1H-吡唑并[3,4-b]吡啶-3-胺及其衍生物的制备方法 |
| CA2696288A1 (en) | 2007-08-15 | 2009-02-19 | Schering Corporation | 6-substituted sulfonyl azabicyclo[3.2.1]octanes useful to inhibit 11.beta.-hydroxysteroid dehydrogenase type-1 |
| US8841304B2 (en) | 2008-01-08 | 2014-09-23 | Array Biopharma, Inc. | Pyrrolopyridines as kinase inhibitors |
| CN101965347B (zh) | 2008-01-09 | 2013-01-02 | 阵列生物制药公司 | 作为激酶抑制剂的吡唑并吡啶 |
| EP2247748A2 (en) * | 2008-02-13 | 2010-11-10 | Elan Pharma International Limited | Alpha-synuclein kinase |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| RS59144B1 (sr) | 2013-11-13 | 2019-09-30 | Vertex Pharma | Inhibitori replikacije virusa influence |
| HRP20181272T1 (hr) | 2013-11-13 | 2018-10-05 | Vertex Pharmaceuticals Incorporated | Postupci priprave inhibitora replikacije virusa influence |
| JP6704416B2 (ja) | 2015-05-13 | 2020-06-03 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | インフルエンザウイルスの複製の阻害剤を調製する方法 |
| JP6857617B2 (ja) | 2015-05-13 | 2021-04-14 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | インフルエンザウイルスの複製の阻害剤 |
| CN116687951B (zh) * | 2023-06-06 | 2026-01-02 | 河北渤腾医药技术有限公司 | 一种plk1的干扰rna及其应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001522842A (ja) * | 1997-11-12 | 2001-11-20 | ブリストル−マイヤーズ スクイブ カンパニー | サイクリン依存性キナーゼのアミノチアゾール系阻害剤 |
| JP2002523448A (ja) * | 1998-08-28 | 2002-07-30 | サイオス インコーポレイテッド | p38−αキナーゼのインヒビター |
| WO2003000688A1 (en) * | 2001-06-21 | 2003-01-03 | Aventis Pharma Limited | Azaindoles |
| JP2003500470A (ja) * | 1999-05-28 | 2003-01-07 | アボット・ラボラトリーズ | 細胞増殖抑制剤 |
| WO2003045949A1 (en) * | 2001-11-26 | 2003-06-05 | Smithkline Beecham P.L.C. | Pyrazolopyridine derivatives |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5420297A (en) * | 1990-10-24 | 1995-05-30 | Fujisawa Pharmaceutical Co., Ltd. | Peptides having substance P antagonistic activity |
| GB9113219D0 (en) | 1991-06-19 | 1991-08-07 | Fujisawa Pharmaceutical Co | Peptide compound,processes for preparation thereof and pharmaceutical composition comprising the same |
| US5654400A (en) * | 1991-10-04 | 1997-08-05 | Fujisawa Pharmaceutical Co., Ltd. | Process for making peptide compounds having tachykinin antagonistic activity |
| JP3485198B2 (ja) * | 1993-11-10 | 2004-01-13 | 富士写真フイルム株式会社 | ヒドラジン化合物及び該化合物を含むハロゲン化銀写真感光材料 |
| PL181323B1 (pl) | 1994-02-18 | 2001-07-31 | Boehringer Ingelheim Pharma | 2-heteroarylo-5,11-dihydro-6H-dipirydo[3,2-b:2’,3'-e][1,4] diazepinyi ich zastosowanie w zapobieganiu i leczeniu zakazen HIV PL PL PL |
| GB9412719D0 (en) | 1994-06-24 | 1994-08-17 | Erba Carlo Spa | Substituted azaindolylidene compounds and process for their preparation |
| JPH11501289A (ja) | 1994-12-02 | 1999-02-02 | 藤沢薬品工業株式会社 | No介在疾患の予防および/または治療のためのペプチド化合物 |
| US5837704A (en) * | 1995-02-17 | 1998-11-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | 2-heteroaryl-5,11-dihydro-6H-dipyrido 3,2-B:2',3'-E! 1,4!diazepines and their use in the prevention or treatment of HIV infection |
| US5804585A (en) | 1996-04-15 | 1998-09-08 | Texas Biotechnology Corporation | Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin |
| US6537999B2 (en) * | 1996-06-06 | 2003-03-25 | Duquesne University Of The Holy Ghost | Pyrimidine derivatives and methods of making and using these derivatives |
| JP4028607B2 (ja) | 1996-07-24 | 2007-12-26 | 富山化学工業株式会社 | 新規なセファロスポリン誘導体またはその塩 |
| US6025366A (en) * | 1998-04-02 | 2000-02-15 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| EP1071423A1 (en) | 1998-04-02 | 2001-01-31 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| CA2325995A1 (en) | 1998-04-02 | 1999-10-14 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US6110931A (en) * | 1998-04-02 | 2000-08-29 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US6319660B1 (en) * | 1998-12-28 | 2001-11-20 | Eastman Kodak Company | Color photographic element containing speed improving compound |
| CZ27399A3 (cs) * | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| US6309811B2 (en) * | 1999-07-21 | 2001-10-30 | Eastman Kodak Company | Color photographic element containing nitrogen heterocycle derivative and inhibitor releasing coupler |
| EP1252154A1 (en) * | 2000-02-04 | 2002-10-30 | Pfizer Products Inc. | Heterocyclic amide derivatives |
| GB0021670D0 (en) | 2000-09-04 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| US6770645B2 (en) * | 2001-03-16 | 2004-08-03 | Pfizer Inc. | Pharmaceutically active compounds |
| GB0106661D0 (en) | 2001-03-16 | 2001-05-09 | Pfizer Ltd | Pharmaceutically active compounds |
| WO2003000690A1 (en) | 2001-06-25 | 2003-01-03 | Aventis Pharmaceuticals Inc. | Synthesis of heterocyclic compounds employing microwave technology |
| TW200403243A (en) * | 2002-07-18 | 2004-03-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
| CA2493625A1 (en) | 2002-07-25 | 2004-02-19 | Pharmacia Italia S.P.A. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| GB0218800D0 (en) | 2002-08-13 | 2002-09-18 | Celltech R&D Ltd | Chemical compounds |
| GB0226583D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
| KR101312736B1 (ko) * | 2003-02-27 | 2013-09-27 | 팔라우 파르마 에스에이 | 피라졸로피리딘 유도체 |
| CA2517517C (en) * | 2003-03-03 | 2012-12-18 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| CA2518318A1 (en) | 2003-03-17 | 2004-09-30 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| AU2004232973A1 (en) | 2003-04-18 | 2004-11-04 | Memory Pharmaceuticals Corporation | Pyrazole derivatives as phosphodiesterase 4 inhibitors |
| EP1620095A4 (en) | 2003-04-24 | 2009-04-01 | Merck & Co Inc | HEMMER OF ACT ACTIVITY |
| JP4836788B2 (ja) | 2003-07-23 | 2011-12-14 | エグゼリクシス, インコーポレイテッド | 未分化リンパ腫キナーゼ変調因子及びその使用法 |
| GB0317471D0 (en) | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Novel compounds |
| GB0317482D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
| US7132435B2 (en) * | 2003-07-25 | 2006-11-07 | Pfizer Inc. | Compounds |
| EP1670804A2 (en) | 2003-09-10 | 2006-06-21 | GPC Biotech AG | Heterobicyclic compounds as pharmaceutically active agents |
| CA2542880A1 (en) * | 2003-10-21 | 2005-05-12 | Cyclacel Limited | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy |
| KR100843526B1 (ko) * | 2004-02-27 | 2008-07-03 | 에프. 호프만-라 로슈 아게 | 피라졸의 접합 유도체 |
| MX2007001126A (es) * | 2004-07-27 | 2007-09-25 | Sgx Pharmaceuticals Inc | Moduladores de heterociclo cinasa de anillo fusionado. |
-
2006
- 2006-11-15 US US11/600,311 patent/US8017781B2/en not_active Expired - Fee Related
- 2006-11-15 AU AU2006315436A patent/AU2006315436A1/en not_active Abandoned
- 2006-11-15 WO PCT/US2006/044361 patent/WO2007059219A1/en not_active Ceased
- 2006-11-15 CA CA002628179A patent/CA2628179A1/en not_active Abandoned
- 2006-11-15 JP JP2008541312A patent/JP2009515984A/ja active Pending
- 2006-11-15 CN CNA2006800507344A patent/CN101365700A/zh active Pending
- 2006-11-15 EP EP06837683A patent/EP1948657A1/en not_active Withdrawn
- 2006-11-15 EP EP11191099A patent/EP2514751A1/en not_active Withdrawn
-
2011
- 2011-07-29 US US13/193,739 patent/US8445681B2/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001522842A (ja) * | 1997-11-12 | 2001-11-20 | ブリストル−マイヤーズ スクイブ カンパニー | サイクリン依存性キナーゼのアミノチアゾール系阻害剤 |
| JP2002523448A (ja) * | 1998-08-28 | 2002-07-30 | サイオス インコーポレイテッド | p38−αキナーゼのインヒビター |
| JP2003500470A (ja) * | 1999-05-28 | 2003-01-07 | アボット・ラボラトリーズ | 細胞増殖抑制剤 |
| WO2003000688A1 (en) * | 2001-06-21 | 2003-01-03 | Aventis Pharma Limited | Azaindoles |
| WO2003045949A1 (en) * | 2001-11-26 | 2003-06-05 | Smithkline Beecham P.L.C. | Pyrazolopyridine derivatives |
Non-Patent Citations (1)
| Title |
|---|
| ZEITSCHRIFT FUER NATURFORSCHUNG, B: CHEMICAL SCIENCES, vol. 46, no. 4, JPN6012030504, 1991, pages 541 - 546, ISSN: 0002250652 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019532054A (ja) * | 2016-09-20 | 2019-11-07 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | Trpv4拮抗薬 |
Also Published As
| Publication number | Publication date |
|---|---|
| US8017781B2 (en) | 2011-09-13 |
| EP2514751A1 (en) | 2012-10-24 |
| CA2628179A1 (en) | 2007-05-24 |
| AU2006315436A1 (en) | 2007-05-24 |
| EP1948657A1 (en) | 2008-07-30 |
| US20070179177A1 (en) | 2007-08-02 |
| US8445681B2 (en) | 2013-05-21 |
| CN101365700A (zh) | 2009-02-11 |
| WO2007059219A1 (en) | 2007-05-24 |
| US20120165367A1 (en) | 2012-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2102210B1 (en) | Compounds useful as protein kinase inhibitors | |
| US8410133B2 (en) | Aminopyridines useful as inhibitors of protein kinases | |
| AU2008226457B2 (en) | Aminopyrimidines useful as inhibitors of protein kinases | |
| US8445681B2 (en) | Azaindazoles useful as inhibitors of kinases | |
| JP2009528991A (ja) | プロテインキナーゼの阻害剤として有用なピロロ(3,2−c)ピリジン | |
| WO2008077086A1 (en) | Aminopyrimidines useful as inhibitors of protein kinases | |
| CN101679378A (zh) | 用作激酶抑制剂的噻唑和吡唑 | |
| JP2010528021A (ja) | キナーゼのインヒビターとして有用なチアゾールおよびピラゾール | |
| KR20110039278A (ko) | 단백질 키나제 억제제 | |
| JP2009533452A (ja) | タンパク質キナーゼの阻害剤として有用なチオフェン−カルボキサミド | |
| US20130310418A1 (en) | Azaindazoles useful as inhibitors of kinases | |
| EP2019826B1 (en) | Thiophene-carboxamides useful as inhibitors of protein kinases | |
| HK1125108A (en) | Azaindazoles useful as inhibitors of kinases | |
| HK1130788A (en) | Thiophene-carboxamides useful as inhibitors of protein kinases | |
| HK1141512A (en) | Compounds useful as protein kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091106 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091106 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101101 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120612 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120613 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120912 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120920 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121210 |